ClinicalTrials.gg
CompletedNCT02963701Updated Sep 27, 2018Results posted

Bioequivalence of a Fixed Dose Combination Tablet Containing 400 mg Ibuprofen and 60 mg Pseudoephedrine-HCl Compared to Two Film Coated Fixed Dose Combination Tablets RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) Administered in Healthy Subjects

A Phase 1 interventional study of Ibuprofen and Pseudoephedrine-HCl in Healthy Volunteers, sponsored by Boehringer Ingelheim. Completed at 1 site in South Africa. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-27.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Study summary

Primary objective To demonstrate the bioequivalence of a fixed dose combination tablet containing 400 mg Ibuprofen and 60 mg Pseudoephedrine-HCl vs. RhinAdvil® (2 tablets containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a fixed dose combination tablet with respect to the analytes, ibuprofen and pseudoephedrine.

Secondary objective To assess the bioequivalence of a fixed dose combination tablet containing 400 mg Ibuprofen and 60 mg Pseudoephedrine-HCl vs. RhinAdvil® (2 tablets containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a fixed dose combination tablet with respect to R- and S-ibuprofen (enantiomers of ibuprofen).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females according to the following criteria:
  • Based upon a complete medical history, including physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead (ECG), clinical laboratory tests
  • Age ≥21 to ≤50 years
  • Minimum weight 50kg - both males and females
  • ≥18.5 to ≤29.9 kg/m2
  • Signed and dated written in accordance with Good Clinical Practice (GCP) and local legislation prior to admission to the trial
  • Male or female patients. Women of childbearing potential1 must be ready and able to use highly effective methods of per International Committee on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly e.g. implants, injectables, combined hormonal contraceptives, intrauterine device, or surgical sterilisation (including hysterectomy). In addition to this, also a barrier method (e.g. male condom) will be required, if the female is not surgically sterilised. A list of contraception methods meeting these criteria is provided in the patient information. Abstaining from sexual activity (if this is the usual lifestyle of the subject) is considered an acceptable method of birth control.

Exclusion criteria

Exclusion criteria:

  • Any finding of the medical examination (including Blood Pressure, Pulse Rate and ) deviating from normal and of clinical relevance at the discretion of the investigator
  • Any evidence of a concomitant disease
  • Any relevant Gastrointestinal (e.g. ulcera, hernia, bleedings and spasm), hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Any relevant surgery of the gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or relevant neurological disorders at the discretion of the investigator
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or (including allergy to drug or its ) as judged clinically relevant by the investigator
  • Intake of drugs with a long half-life (>24 hours) within at least 1 month or less than 10 half-lives of the respective drug prior to first drug administration
  • Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 14 days prior to randomisation
  • Participation in another trial with an drug within 2 months prior to administration or during the trial
  • Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
  • Inability to refrain from smoking on trial days as judged by the investigator
  • Alcohol abuse (average consumption of more than 2 units per day for females and more than 3 units per day for males)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration of the trial drug in this study)
  • Excessive physical activities within 1 week prior to randomisation or during the trial
  • Any laboratory value outside the reference range that is of clinical relevance at the discretion of the investigator
  • Inability to comply with dietary regimen of the study centre
  • Unwilling to avoid excessive sunlight exposure
  • Use of drugs which might reasonably influence the results of the trial or that prolong the /corrected QT interval (QTc) within 14 days prior to administration or during the trial, and CYP2C8m substrates such as amiodarone, amodiaquine, paclitaxel, rosiglitazone, pioglitazone and repaglinide or CYP2C9 such as warfarin, tolbutamide, phenytoin, losartan, acenocoumarol within 1 month or six half-lives (whichever is greater)
  • A marked baseline prolongation of the QTc B interval (e.g., repeated demonstration of a QTc B interval >450 ms)
  • A history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)

Special exclusion criteria:

  • Subjects with history of bronchospasm, rhinitis or urticaria associated with Nonsteroidal anti-inflammatory drug (NSAID) - Asthma
  • Risk of or manifested narrow-angle glaucoma
  • Risk of urinary retention due to urethro-prostatic diseases / prostatic enlargement
  • Subjects with the rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase deficiency
  • Regular treatment with any systemically available medication (except hormonal and hormonal replacement therapy e.g. estrogens, L-thyroxine)
  • Subjects, who report a frequent occurrence of migraine attacks
  • For female subjects of only:

Positive pregnancy test, pregnancy or planning to become pregnant during the study or within 2 months after study completion

  • No adequate contraception during the study including three months before first dosing until 2 month after study completion.
  • Lactation

Administrative reasons:

  • Subjects suspected or known not to follow instructions
  • Subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the study

The exclusion criteria are chosen to assure that subjects with specific risks for administration of the investigational medicinal products and subjects with conditions, which may have an impact on pharmacokinetic parameters, cannot be included

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Ibuprofen+Pseudoephedrine-HCl

    Fixed dose combination

    Drug: Ibuprofen · Drug: Pseudoephedrine-HCl

  • Active comparator
    Ibuprofen+Pseudoephedrine-HCl (RhinAdvil®)

    Fixed Dose Combination

    Drug: Ibuprofen · Drug: Pseudoephedrine-HCl

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Ibuprofen. (AUC0-tz)

    This endpoint calculates area under the concentration-time curve of Ibuprofen in plasma over the time interval from 0 to the time of last quantifiable time point.

    Time frame: Samples were collected Pre-dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

  2. Maximum Concentration of Ibuprofen in Plasma (Cmax).

    This outcome is maximum measured concentration of the Ibuprofen in plasma

    Time frame: Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

  3. Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Pseudoephedrine (AUC0-tz).

    This endpoint calculates area under the concentration-time curve of Pseudoephedrine in plasma over the time interval from 0 to the time of last quantifiable time point.

    Time frame: Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

  4. Maximum Concentration of Pseudoephedrine in Plasma (Cmax).

    This outcome is maximum measured concentration of the Pseudoephedrine in plasma

    Time frame: Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

Secondary outcomes

  1. Area Under the Concentration-time Curve of Ibuprofen in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).

    This endpoint calculates area under the concentration-time curve of Ibuprofen in plasma over the time interval from 0 extrapolated to infinity

    Time frame: Samples were collected Pre-dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

  2. Area Under the Concentration-time Curve of Pseudoephedrine in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).

    This endpoint calculates area under the concentration-time curve of Pseudoephedrine in plasma over the time interval from 0 extrapolated to infinity

    Time frame: Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

  3. AUC0-tz of R-Ibuprofen

    This endpoint calculates area under the concentration-time curve of R-Ibuprofen in plasma over the time interval from 0 to the time of last quantifiable time point.

    Time frame: Samples were collected Pre-dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

  4. AUC0-∞ of R-Ibuprofen

    This endpoint calculates area under the concentration-time curve of R-Ibuprofen in plasma over the time interval from 0 extrapolated to infinity

    Time frame: Samples were collected Pre-dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

  5. Cmax of R-Ibuprofen

    This outcome is maximum measured concentration of the R-Ibuprofen in plasma

    Time frame: Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

  6. AUC0-tz of S-Ibuprofen

    This endpoint calculates area under the concentration-time curve of S-Ibuprofen in plasma over the time interval from 0 to the time of last quantifiable time point.

    Time frame: Samples were collected Pre-dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

  7. AUC0-∞ of S-Ibuprofen

    This endpoint calculates area under the concentration-time curve of S-Ibuprofen in plasma over the time interval from 0 extrapolated to infinity

    Time frame: Samples were collected Pre-dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

  8. Cmax of S-Ibuprofen

    This outcome is maximum measured concentration of the S-Ibuprofen in plasma

    Time frame: Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

  9. S/R-ibuprofen Ratio for AUC0-tz

    AUC0-tz S-ibuprofen / AUC0-tz R-ibuprofen

    Time frame: Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.

07

Results

Posted Sep 27, 2018

Participant flow

Period 1 (Including Washout) (2 Days)
Participant flow — Period 1 (Including Washout) (2 Days)
MilestoneTreatment Sequence 1 (T-R)Treatment Sequence 2 (R-T)
Started2828
Completed2728
Not completed10
Withdrew: Withdrawal by subject10
Period 2 (2 Days)
Participant flow — Period 2 (2 Days)
MilestoneTreatment Sequence 1 (T-R)Treatment Sequence 2 (R-T)
Started2728
Completed2728
Not completed00

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Ibuprofen. (AUC0-tz)

This endpoint calculates area under the concentration-time curve of Ibuprofen in plasma over the time interval from 0 to the time of last quantifiable time point.

Time frame:
Samples were collected Pre-dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · Hour nano gram per milliliter (h*ng/mL)
Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Ibuprofen. (AUC0-tz)
Hour nano gram per milliliter (h*ng/mL)Reference Product (R)Test Product (T)
Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Ibuprofen. (AUC0-tz)140500 ± 23.66139300 ± 19.30
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · T/r ratio (%): 99.16 · 90% CI 96.52 to 101.89The estimated parameter was the adjusted geometric mean ratios (%) of Test and Reference products. The parameter dispersion type (Standard Deviation) was actually the intra-individual geometric coefficient of variation (%).
PrimaryMaximum Concentration of Ibuprofen in Plasma (Cmax).

This outcome is maximum measured concentration of the Ibuprofen in plasma

Time frame:
Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · Nano gram per milliliter (ng/mL)
Maximum Concentration of Ibuprofen in Plasma (Cmax).
Nano gram per milliliter (ng/mL)Reference Product (R)Test Product (T)
Maximum Concentration of Ibuprofen in Plasma (Cmax).33580 ± 26.1629940 ± 20.80
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · T/r ratio (%): 89.16 · 90% CI 83.88 to 94.76The estimated parameter was the adjusted geometric mean ratios (%) of Test and Reference products. The parameter dispersion type (Standard Deviation) was actually the intra-individual geometric coefficient of variation (%).
PrimaryArea Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Pseudoephedrine (AUC0-tz).

This endpoint calculates area under the concentration-time curve of Pseudoephedrine in plasma over the time interval from 0 to the time of last quantifiable time point.

Time frame:
Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Pseudoephedrine (AUC0-tz).
h*ng/mLReference Product (R)Test Product (T)
Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Pseudoephedrine (AUC0-tz).2547 ± 22.222540 ± 22.45
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · T/r ratio (%): 99.75 · 90% CI 95.73 to 103.95The estimated parameter was the adjusted geometric mean ratios \[%\] of Test and Reference products. The parameter dispersion type (Standard Deviation) was actually the intra-individual geometric coefficient of variation \[%\].
PrimaryMaximum Concentration of Pseudoephedrine in Plasma (Cmax).

This outcome is maximum measured concentration of the Pseudoephedrine in plasma

Time frame:
Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · ng/mL
Maximum Concentration of Pseudoephedrine in Plasma (Cmax).
ng/mLReference Product (R)Test Product (T)
Maximum Concentration of Pseudoephedrine in Plasma (Cmax).320.4 ± 22.09327.4 ± 25.28
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · T/r ratio (%): 102.16 · 90% CI 97.30 to 107.27The estimated parameter was the adjusted geometric mean ratios \[%\] of Test and Reference products. The parameter dispersion type \[SD\] was actually the intra-individual geometric coefficient of variation \[%\].
SecondaryArea Under the Concentration-time Curve of Ibuprofen in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).

This endpoint calculates area under the concentration-time curve of Ibuprofen in plasma over the time interval from 0 extrapolated to infinity

Time frame:
Samples were collected Pre-dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve of Ibuprofen in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).
h*ng/mLReference Product (R)Test Product (T)
Area Under the Concentration-time Curve of Ibuprofen in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).143000 ± 22.88141600 ± 18.72
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · T/r ratio (%): 98.97 · 90% CI 96.44 to 101.57The estimated parameter was the adjusted geometric mean ratios (%)of Test and Reference products. The parameter dispersion type (Standard Deviation) was actually the intra-individual geometric coefficient of variation (%).
SecondaryArea Under the Concentration-time Curve of Pseudoephedrine in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).

This endpoint calculates area under the concentration-time curve of Pseudoephedrine in plasma over the time interval from 0 extrapolated to infinity

Time frame:
Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve of Pseudoephedrine in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).
h*ng/mLReference Product (R)Test Product (T)
Area Under the Concentration-time Curve of Pseudoephedrine in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).2622 ± 23.072614 ± 23.65
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · T/r ratio (%): 99.67 · 90% CI 95.48 to 104.04The estimated parameter was the adjusted geometric mean ratios (%) of Test and Reference products. The parameter dispersion type (Standard Deviation) was actually the intra-individual geometric coefficient of variation (%).
SecondaryAUC0-tz of R-Ibuprofen

This endpoint calculates area under the concentration-time curve of R-Ibuprofen in plasma over the time interval from 0 to the time of last quantifiable time point.

Time frame:
Samples were collected Pre-dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · h*ng/mL
AUC0-tz of R-Ibuprofen
h*ng/mLReference Product (R)Test Product (T)
AUC0-tz of R-Ibuprofen68520 ± 28.0865760 ± 21.55
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · T/r ratio (%): 95.96 · 90% CI 91.70 to 100.40The estimated parameter was the adjusted geometric mean ratios (%) of Test and Reference products. The parameter dispersion type (Standard Deviation) was actually the intra-individual geometric coefficient of variation (%).
SecondaryAUC0-∞ of R-Ibuprofen

This endpoint calculates area under the concentration-time curve of R-Ibuprofen in plasma over the time interval from 0 extrapolated to infinity

Time frame:
Samples were collected Pre-dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · h*ng/mL
AUC0-∞ of R-Ibuprofen
h*ng/mLReference Product (R)Test Product (T)
AUC0-∞ of R-Ibuprofen69420 ± 27.7666740 ± 21.51
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · T/r ratio (%): 96.12 · 90% CI 91.92 to 100.51The estimated parameter was the adjusted geometric mean ratios (%) of Test and Reference products. The parameter dispersion type (Standard Deviation) was actually the intra-individual geometric coefficient of variation (%).
SecondaryCmax of R-Ibuprofen

This outcome is maximum measured concentration of the R-Ibuprofen in plasma

Time frame:
Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · ng/mL
Cmax of R-Ibuprofen
ng/mLReference Product (R)Test Product (T)
Cmax of R-Ibuprofen18630 ± 29.3416910 ± 21.98
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · T/r ratio (%): 90.83 · 90% CI 84.87 to 97.21The estimated parameter was the adjusted geometric mean ratios (%) of Test and Reference products. The parameter dispersion type (Standard Deviation) was actually the intra-individual geometric coefficient of variation (%).
SecondaryAUC0-tz of S-Ibuprofen

This endpoint calculates area under the concentration-time curve of S-Ibuprofen in plasma over the time interval from 0 to the time of last quantifiable time point.

Time frame:
Samples were collected Pre-dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · h*ng/mL
AUC0-tz of S-Ibuprofen
h*ng/mLReference Product (R)Test Product (T)
AUC0-tz of S-Ibuprofen70290 ± 24.9071610 ± 23.25
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · T/r ratio (%): 101.86 · 90% CI 99.33 to 104.46The estimated parameter was the adjusted geometric mean ratios (%) of Test and Reference products. The parameter dispersion type (Standard Deviation) was actually the intra-individual geometric coefficient of variation (%).
SecondaryAUC0-∞ of S-Ibuprofen

This endpoint calculates area under the concentration-time curve of S-Ibuprofen in plasma over the time interval from 0 extrapolated to infinity

Time frame:
Samples were collected Pre-dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · h*ng/mL
AUC0-∞ of S-Ibuprofen
h*ng/mLReference Product (R)Test Product (T)
AUC0-∞ of S-Ibuprofen72270 ± 23.8473460 ± 22.21
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · T/r ratio (%): 101.65 · 90% CI 99.40 to 103.95The estimated parameter was the adjusted geometric mean ratios (%) of Test and Reference products. The parameter dispersion type (Standard Deviation) was actually the intra-individual geometric coefficient of variation (%).
SecondaryCmax of S-Ibuprofen

This outcome is maximum measured concentration of the S-Ibuprofen in plasma

Time frame:
Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · ng/mL
Cmax of S-Ibuprofen
ng/mLReference Product (R)Test Product (T)
Cmax of S-Ibuprofen15050 ± 22.2813020 ± 22.36
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · T/r ratio (%): 86.53 · 90% CI 82.03 to 91.28The estimated parameter was the adjusted geometric mean ratios (%) of Test and Reference products. The parameter dispersion type (Standard Deviation) was actually the intra-individual geometric coefficient of variation (%).
SecondaryS/R-ibuprofen Ratio for AUC0-tz

AUC0-tz S-ibuprofen / AUC0-tz R-ibuprofen

Time frame:
Samples were collected pre dose and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 30:00 hours post dose.
Reported as:
Geometric mean · Ratio
S/R-ibuprofen Ratio for AUC0-tz
RatioReference Product (R)Test Product (T)
S/R-ibuprofen Ratio for AUC0-tz1.026 ± 23.261.089 ± 23.30
Statistical analysis
  • Reference Product (R) vs Test Product (T) · ANOVA · Ratio (%): 106.17 · 90% CI 101.30 to 111.26The estimated parameter was the adjusted geometric mean ratios (%) of Test and Reference products. The parameter dispersion type (Standard Deviation) was actually the intra-individual geometric coefficient of variation (%).

Adverse events

Collected over From first drug administration till 7 days after last drug administration; up to 14 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reference Product (R)0/55 (0%)0/55 (0%)0/55 (0%)
Test Product (T)0/56 (0%)0/56 (0%)0/56 (0%)

Baseline characteristics

Baseline characteristics were calculated on Safety Population. All subjects who received at least one dose of study medication were included in the safety population.

Age, Continuous
Age, Continuous(Years)Treatment Sequence 1 (T-R)Treatment Sequence 2 (R-T)Total
Mean28.5 ± 6.7729.2 ± 8.0328.8 ± 7.37
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence 1 (T-R)Treatment Sequence 2 (R-T)Total
Female121224
Male161632
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment Sequence 1 (T-R)Treatment Sequence 2 (R-T)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American202141
White7613
More than one race000
Other112
08

Study locations

1 site
  • Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)
    Bloemfontein, 9301, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Jan 2017, 1 month.

Results were first posted in Sep 2018, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2016
First posted
Nov 15, 2016
StartActual
Dec 20, 2016
Primary completionActual
Jan 31, 2017
CompletionActual
Feb 8, 2017
Results first posted
Sep 27, 2018
Last update
Sep 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02963701
Responsible party
Sponsor
First posted
Nov 15, 2016
Start date
Dec 20, 2016
Primary completion
Jan 31, 2017
Completion
Feb 8, 2017
Results posted
Sep 27, 2018
Last update
Sep 27, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Pseudoephedrine

Start the discussion